Intellia Therapeutics Management
Management Kriterienprüfungen 2/4
Intellia Therapeutics' CEO ist John Leonard , ernannt in Jan 2018, hat eine Amtszeit von 6.42 Jahren. Die jährliche Gesamtvergütung beträgt $11.66M , bestehend aus 5.7% Gehalt und 94.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.86% der Aktien des Unternehmens, im Wert von $20.90M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.7 Jahre bzw. 9.2 Jahre.
Wichtige Informationen
John Leonard
Geschäftsführender
US$11.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 5.7% |
| Amtszeit als Geschäftsführer | 6.4yrs |
| Eigentum des Geschäftsführers | 0.9% |
| Durchschnittliche Amtszeit des Managements | 5.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 9.2yrs |
Jüngste Management Updates
Recent updates
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Jul 05Intellia Makes History. Can It Deliver A Cure?
Jun 28Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$486m |
| Dec 31 2023 | US$12m | US$660k | -US$481m |
| Sep 30 2023 | n/a | n/a | -US$462m |
| Jun 30 2023 | n/a | n/a | -US$453m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$10m | US$630k | -US$474m |
| Sep 30 2022 | n/a | n/a | -US$442m |
| Jun 30 2022 | n/a | n/a | -US$400m |
| Mar 31 2022 | n/a | n/a | -US$369m |
| Dec 31 2021 | US$10m | US$600k | -US$268m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$185m |
| Mar 31 2021 | n/a | n/a | -US$149m |
| Dec 31 2020 | US$4m | US$580k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$120m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$109m |
| Dec 31 2019 | US$904k | US$559k | -US$100m |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | US$10m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$83m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$3m | US$396k | -US$68m |
Vergütung im Vergleich zum Markt: JohnDie Gesamtvergütung ($USD11.66M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD6.83M).
Entschädigung vs. Einkommen: JohnDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
John Leonard (67 yo)
6.4yrs
Amtszeit
US$11,657,262
Vergütung
Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 6.4yrs | US$11.66m | 0.86% $ 19.0m | |
| Executive VP | 5.7yrs | US$3.82m | 0.019% $ 412.9k | |
| Executive VP & Chief Scientific Officer | 5.1yrs | US$4.19m | 0.020% $ 443.6k | |
| Executive VP | 3yrs | US$3.99m | 0.018% $ 406.5k | |
| Executive VP & Chief Medical Officer | 4.2yrs | US$4.26m | 0.030% $ 671.7k | |
| Founder & Member of Scientific Advisor Board | 10.1yrs | US$11.27m | keine Daten | |
| Co-Founder | 10.1yrs | US$311.57k | keine Daten | |
| Founder and Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten |
5.7yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von NTLA ist erfahren und erfahren (durchschnittliche Amtszeit: 5.6 Jahre).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 9.9yrs | US$11.66m | 0.86% $ 19.0m | |
| Founder & Member of Scientific Advisor Board | no data | US$11.27m | keine Daten | |
| Founder and Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | 9.2yrs | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | 9.2yrs | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Founder & Member of Scientific Advisor Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 9.4yrs | keine Daten | keine Daten | |
| Independent Chairman of the Board | 6.9yrs | US$499.94k | 0.011% $ 233.8k | |
| Independent Director | 1.2yrs | US$996.21k | 0.0070% $ 155.8k |
9.2yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: NTLADie Vorstandsmitglieder gelten als erfahren (9.2 Jahre durchschnittliche Amtszeit).